Psychometric Properties of Patient-Reported Outcome Measures for Cancer-Related Cognitive Impairment: A Systematic Review.
6 affiliations
- 1Department of Nursing, Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Dongdan Campus), Beijing, China.
- 2School of Nursing, Chinese Academy of Medical Sciences-Peking Union Medical College, Beijing, China.
- 3Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 4Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 5Department of Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 6Department of Health and Medical Care, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
Objective
To systematically identify and evaluate the psychometric properties of patient-reported outcome measures for assessing cancer-related cognitive impairment.Methods
This systematic review was conducted in accordance with COSMIN methodology. Five databases (PubMed, Embase, CINAHL, Web of Science and PsycInfo) were searched from inception to December 31, 2025. Studies reporting the development and/or validation of PROMs for assessing CRCI were eligible for inclusion. Methodological quality was assessed using the COSMIN Risk of Bias Checklist. Psychometric properties were rated using the COSMIN criteria, and the quality of evidence for each instrument was graded using a modified GRADE approach.Results
A total of 28 studies encompassing 19 PROMs for assessing CRCI were included. Measurement error and responsiveness were each evaluated in one study. The EORTC IADL-BN32 was the only Grade A instrument, although its evidence was restricted to adults with brain tumours. The other 18 instruments received Grade B recommendations, indicating that they have potential for use but require further validation.Conclusions
The EORTC IADL-BN32 is currently the best-supported instrument for adults with brain tumours, but its applicability to broader CRCI populations remains uncertain and requires further validation. Evidence for interpreting change was particularly limited, since measurement error and responsiveness were each evaluated in only one study, and neither yielded sufficient evidence. Instrument selection should be population- and purpose-specific, and further validation of measurement error, responsiveness and cross-cultural validity is required. Future studies should adhere to COSMIN guidelines to ensure comprehensive evaluation of all psychometric properties during instrument development and validation.Registration
PROSPERO (CRD420251033872).
Related
- Content Validity and Psychometric Properties Assessment of the Virtual Reality Functional Capacity Assessment Tool and Application in Multiregional Clinical Trials of Cognitive Impairment Associated with Schizophrenia.
- Cross-cultural adaptation and comparative psychometric evaluation of four patient-reported outcome measures for breast cancer-related lymphedema: measurement properties and clinical discrimination
- Psychometric properties of a short knowledge test to evaluate awareness of external ventricular drain care practices among Chinese nurses: a Rasch model analysis of an efficient 7-item self-reported assessment tool
- Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.
- Cognitive transfer and durability of computerised cognitive training in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials
BibTeX
@article{lan2026psychometric,
title = {{Psychometric Properties of Patient-Reported Outcome Measures for Cancer-Related Cognitive Impairment: A Systematic Review.}},
author = {Yuan-Mei Lan and Zi-Tian Zhu and Hao-Qi Wu and Yue-Ying Feng and Tian-Chao Chen and Yun-Feng Bai and Chen Zhu and Ying Liu and Ming-Xi Zhao and Yuan Xu and Xin-Juan Wu},
journal = {Psycho-oncology},
year = {2026},
month = oct,
doi = {10.1002/pon.70619},
url = {https://europepmc.org/article/MED/42894374},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Psychometric Properties of Patient-Reported Outcome Measures for Cancer-Related Cognitive Impairment: A Systematic Review.
AU - Yuan-Mei Lan
AU - Zi-Tian Zhu
AU - Hao-Qi Wu
AU - Yue-Ying Feng
AU - Tian-Chao Chen
AU - Yun-Feng Bai
AU - Chen Zhu
AU - Ying Liu
AU - Ming-Xi Zhao
AU - Yuan Xu
AU - Xin-Juan Wu
PY - 2026
DA - 2026/10/01
JO - Psycho-oncology
DO - 10.1002/pon.70619
UR - https://europepmc.org/article/MED/42894374
AB - Objective To systematically identify and evaluate the psychometric properties of patient-reported outcome measures for assessing cancer-related cognitive impairment.Methods This systematic review was conducted in accordance with COSMIN methodology. Five databases (PubMed, Embase, CINAHL, Web of Science and PsycInfo) were searched from inception to December 31, 2025. Studies reporting the development and/or validation of PROMs for assessing CRCI were eligible for inclusion. Methodological quality was assessed using the COSMIN Risk of Bias Checklist. Psychometric properties were rated using the COSMIN criteria, and the quality of evidence for each instrument was graded using a modified GRADE approach.Results A total of 28 studies encompassing 19 PROMs for assessing CRCI were included. Measurement error and responsiveness were each evaluated in one study. The EORTC IADL-BN32 was the only Grade A instrument, although its evidence was restricted to adults with brain tumours. The other 18 instruments received Grade B recommendations, indicating that they have potential for use but require further validation.Conclusions The EORTC IADL-BN32 is currently the best-supported instrument for adults with brain tumours, but its applicability to broader CRCI populations remains uncertain and requires further validation. Evidence for interpreting change was particularly limited, since measurement error and responsiveness were each evaluated in only one study, and neither yielded sufficient evidence. Instrument selection should be population- and purpose-specific, and further validation of measurement error, responsiveness and cross-cultural validity is required. Future studies should adhere to COSMIN guidelines to ensure comprehensive evaluation of all psychometric properties during instrument development and validation.Registration PROSPERO (CRD420251033872).
SN - 1057-9249
SN - 1099-1611
ER -